The effect of calmodulin inibitors on the circadian rhythm of locomotor activity and on the rhythm of suprachiasmatic nuclear (SCN) neuron firing rate recorded in vitro from hypothalamic slices was examined. Trifluoperazine produces changes in a dose-dependent manner in the phase of the activity rhythm, with phase advances throughout most of the subjective day extending into the subjective night. These phase changes in the activity rhythm occur rapidly and without induction of locomotor activity at the time of treatment. Similarly, trifluoperazine and the naphthalenesulfonamide W-7 produce changes in phase delays in the subjective night extending into early subjective day. The effects are greater with respect to amplitude when measured acutely after treatment than in the next cycle, and both the acute and next-day effects are greater than those observed in vivo, indicating that data from in vitro studies need to be interpreted with caution. These observations indicate that calmodulin inhibitors affect rhythms directly in vivo by altering SCN neuron pacemaker function, as this reflects involvement of calcium-calmodulin binding with activation of a calmodulin-dependent kinase, either to alter intracellular cAMP levels or to alter gene expression directly to modulate the phase of the SCN clock. Circadian rhythms are ubiquitous features of the adaptation of eukaryotic organisms to their environment. The analysis of circadian function has progressed rapidly over the last 30 years; despite this progress, however, we still have only limited and fragmentary information concerning the molecular and biochemical mechanisms by which circadian rhythms are generated and regulated. As with so many functions, it is clear that calcium is crucial to circadian function (Nakashima, 1986; McMahon and Block, 1987; Edmunds, 1988 ), but the majority of studies have been carried out on lower organisms. In mammals, the suprachiasmatic nucleus (SCN) of the hypothalamus is a circadian pacemaker (Moore, 1983; Meijer and Rietveld, 1989) . Recent studies have demonstrated that calcium ions are essential for the expression of the normal firing pattern of SCN neurons (Shibata et al., 1984; Sugimori et al., 1986; Thomson, 1984) and of the circadian rhythm in firing rate (Shibata et al., 1984; ) and 2-deoxyglucose uptake Shibata and Moore, 1988) . A recent study has shown that synchronous ultradian neuronal activity continues in the SCN neurons in slices still produce periodic and synchronous action potentials.
dependent calcium channels and calcium-dependent synaptic transmission, had no effect on the phase of the circadian rhythm in firing rate in vitro (Prosser et al., 1992) . These studies suggest that whereas calcium is necessary for the overt expression of circadian function, calcium-dependent synaptic transmission is not essential for the maintenance of endogenous rhythmicity in SCN cells.
It is well know, however, that calcium is a major second messenger in neurons. Activation of ligand-gated and voltage-dependent calcium channels results in a flow of calcium across the neuronal plasma membrane. Among other actions, calcium binds to calmodulin, which initiates the activation of calmodulin-dependent protein kinases (Means et al., 1991 ) . There is a large number of these kinases with multiple actions, including modulation of synaptic transmission (Nicoll et al., 1990; Waxham et al., 1993) , regulation of the cell cycle (Lu and Means, 1993) , and regulation of gene expression (Bading et al., 1993) . Since it is clear that calcium is necessary for the expression of circadian function in the SCN, and likely that a calcium-calmodulin process is involved in mediating the functional effects of afferent input on SCN neurons, we have initiated a program of study of this process by analyzing the effects of calmodulin inhibitors on circadian function in vivo and in vitro.
MATERIALS AND METHODS

ANIMALS
For in vitro studies, male Wistar or Sprague-Dawley rats (200-250 g) were maintained in plastic cages in a standard animal facility with free access to food and water in a light-dark cycle (LD 12:12;  lights-on hr; approximately 200 lux) for at least 2 weeks after receipt into the laboratory.
For the in vivo analysis of activity rhythms, adult male golden hamsters (Mesocricetus auratus, 90-110 g) were housed individually in transparent plastic cages (20 x 30 x 14 cm), each equipped with a 13-cm-diameter running wheel that activated a microswitch with each revolution. Wheel-running activity was recorded continuously by an event recorder.
The animals were maintained in constant illumination or in constant darkness with free access to food and water. After a minimum of 10 days in constant conditions, the animals each received an intraperitoneal injection of drug or sterile saline. The injections were given at circadian time (CT) 0, 4, 8, 12, 16, or 20. The onset of activity was noted before and after each manipulation. A visually fitted line was drawn through the points representing the onset of activity before and after manipulation, and the distance between the two lines was used to calculate a phase response.
SLICE PREPARATION
For the in vitro analysis of the SCN neuron firing rate rhythm, the animals were decapitated under metoxifane anesthesia, and the brains were quickly removed. Coronal hypothalamic slices (450 )JLm thick) were prepared through the SCN with a tissue chopper. The details of the preparation of brain slices, the composition of the Krebs solution used in the recording chamber, the recording electrode, and identification and recording of units have been reported previously (Shibata et al., 1982 (Shibata et al., , 1984 Shibata and Moore, 1988) .
DRUGS
The drugs used were trifluoperazine hydrochloride, chlorpromazine, calmidazolium hydrochloride, cycloheximide, and pentobarbital, all from Sigma. The naphthalenesulfonamides W-5 and W-7 were obtained from Seikagaku Kogyo (Tokyo).
EXPERIMENTS EXPERIMENT 1
Experiment 1 examined the immediate changes in firing rates after drug administration. For this experiment, animals were divided into four groups, each of which was placed into four groups, each of which was placed in a different LD 12:12 cycle with successive 6-hr delays of the time of lights-on (0700-1900 hr, 1300-0100 hr, 1900-0700 hr, 0100-1300 hr). After at least 3 weeks in these conditions, the animals were sacrificed as noted above by decapitation at 0800 hr. After a preincubation of 90 min, the slices were treated with drug or control solution for 1 hr (from 0930-1030 hr), washed, and maintained in a standard Krebs solution for the remainder of the experiment. The only exception to this paradigm was cycloheximide treatment, which extended for 3 hr (0830-1130 hr). From 1300 to 1900 hr, single-unit activity was recorded from each slice, and an average discharge rate for SCN neurons was calculated for successive 2-hr epochs through the 6-hr recording period. With this paradigm, the animals were sacrificed at CT 1, 7, 13, and 19 for successive groups; each treatment was applied for 1 hr centered at CT 3, 9, 15, and 21; and recordings were made during [12] [13] [14] [15] [16] [17] [18] [18] [19] [20] [21] [22] [23] [24] for each group, respectively. As a baseline control for the study, untreated slices from each group were handled as noted above, except that water (0.1 % in Krebs solution) was added to the chambers during the designated treatment period. On each recording day, two sets of slices, control and treated, were used. Untreated slices from each group were prepared at least once a week and analyzed to ensure the stability of the firing rate rhythm.
The treatments applied were as follows: trifluoperazine, 10 ~,M; chlorpromazine, 100 Lm; the active calmodulin inhibitor W-7, 50 [tm; its inactive analogue, W-5, 50 ~,M; pentobarbital, 300 JLM; potassium, 25 mM; and cycloheximide, 11 f.LM. Dose-response curves for the effects of both trifluoperazine and W-7 in both the phase advance and phase delay portions of (PRCs) were obtained (see below). Phase advances and phase delays were calculated for each treatment time by extrapolating a curve from the three mean firing rate points obtained. The data from all of the slices were then used to create a PRC for the effect of each treatment on the circadian rhythm of single-neuron firing rate in the SCN.
--EXPERIMENT 2 Experiment 2 examined the stability of the changes in firing rate after acute drug treatment in vitro. Treatments were performed on day 1, and the peak firing rate was determined on day 2. The firing rates of all of the cells recorded during a single experiment were averaged into 2-hr intervals using 1-hr lags. Prior studies have shown that this procedure yields a pattern of electrical activity for the total population of SCN neurons that varies little for slices from individual animals, with peak firing rates that are a reliable marker of the phase of the SCN pacemaker (Prosser and Gillette, 1989; Shibata et al., 1992) . The drugs used in this experiment were trifluoperazine, 10 f.LM; W-7, 10 JLM; and W-5, 10 f.LM. EXPERIMENT 3 The objective of Experiment 3 was to determine whether the phase changes induced by calmodulin inhibitors in Experiments 1 and 2 would be expressed and maintained in vivo. Hamsters were used because of the precision of their activity rhythms. Treatments were administered at the times noted above. The doses of trifluoperazine used in this experiment were 0.5, 5, and 10.0, and the dose of calmidazolium was 5 mg/kg (i.p.).
RESULTS
EXPERIMENT 1
The data from the untreated control group are shown in Figure 1 . The single-unit recordings from each LD cycle group permit constructing a curve of one full circadian cycle of firing rate of SCN neurons (Fig. 1E ), to which a curve can be fitted (Fig. IF) . This, then, is a reconstruction of a rhythm in firing rate obtained from recordings of 80-230 SCN units for each point shown from untreated slices, and forms a basis for evaluating the effects of treatments on the phase of firing rate rhythm (Fig. 2 ). The rhythm shows a peak at CT 6 and a trough at CT 18, and is very similar to that obtained from control animals in prior studies (Shibata et al., 1982 (Shibata et al., , 1984 Shibata and Moore, 1988 ). The addition of vehicle FIGURE 1. Circadian rhythm in firing rate of SCN neurons in untreated hypothalamic slices in vitro. The animals were sacrificed at different CTs (arrows), and firing rates were recorded for 6 hr and averaged into 3 bins of 2 hr each, indicated by the filled circles (impulses/sec ± SEM). Where no standard error is indicated, it is less than the mark indicating the mean. The slices obtained from the four LD cycles are shown in A-D, and E represents the composite rhythm in firing rate. Sixteen (A), 11 (B), 11 (C), and 12 (D) animals were used, and each mean value represents recordings from 80-230 SCN neurons. In F, a curve is fitted to the points, and this is used in subsequent treatment groups to estimate phase shifts. The CTs are designated in the usual manner, with CT 0 indicating the time of lights-on and CT 12 the time of lights-off in the animal colony. FIGURE 2. Acute effects of treatments on the phase of the SCN circadian rhythm in firing rate. The graphs are as in Figure 1 , with the solid line in each representing a curve fitted to the data from untreated slices. The effects of three treatments are shown to demonstrate the derivation of the PRCs to be shown in Figures 3 and 4 . The treatments are as follows: A, water, 0.1%; B, trifluoperazine, 10 wNt; C, high K+, 25 mM. Each treatment was applied for 1 hr at four different CTs (arrows), and the recordings were performed and data analyzed as for the untreated group. A curve (broken line) is derived for each treatment time in mean hours ± SEM phase advance or phase delay. In this figure, each point represents recordings from 8-16 SCN units.
(water, 0.1%) to the Krebs solution has no effect on the rhythm ( Fig. 2A, Fig. 3 ). Similarly, pentobarbital, which produces a striking decrease in firing rate during the time of administration, does not alter phase of the firing rate rhythm (Fig. 3 ). In contrast, high potassium produces significant changes ( Fig. 3 ), which are nearly opposite to those of the protein synthesis inhibitor cycloheximide, and the active calmodulin inhibitors (trifluoperazine, chlorpromazine, and the naphtalenesulfonamide W-7). The inactive analogue of W-7, W-5, has no effect upon the phase of the rhythm (Fig. 4 ). The effects of the calmodulin inhibitors, trifluoperazine and W-7, are dose-dependent ( Fig. 5 ), indicating that the interpretation of directions of phase shift are correct. It should be noted, though, that some of the apparent phase changes are extremely large (as much as 8 hr), and beyond what would generally be expected in vivo.
EXPERIMENT 2
In Experiment 2, the method of Prosser and Gillette (1989) has been used to determine whether the phase changes noted in Experiment 1 can be maintained in vitro. In a prior study, the mean peak firing rate for untreated slices, 6.0 ± 0.32 hr (Shibata et al., 1992) , is similar to that reported by Prosser and Gillette (1989) . In control slices in the present study, the peak firing rate is also at about Ct 6 on day 2 (CT 6.14 ± 0.14 hr; Fig. 6 ) after control treatment on day 1. This indicates that changing the medium does not alter the phase of the rhythm. When slices are treated on day 1 at CT 7-8 with trifluoperazine (10 [Lm), FIGURE 3. PRCs for changes in the firing rate rhythm of SCN neurons in hypothalamic slices in vitro. This figure shows the PRCs for water (0.1%), pentobarbital (PB 300 ~,M), high K+ (25 mM), and cycloheximide (11 1 >M). Control treatment, water, and pentobarbital have no significant effects on phase, compared to the untreated slices. High K+ produces a PRC with phase delays beginning in the subjective day and extending into the subjective night, with a small phase advance at CT 21. Cycloheximide produces significant phase delays at CT 3 and phase advances at CT 9, with no change at other points. Differences were analyzed using a t test: *p < 0.05, **p < 0.01, ***p < 0.001. In this and Figures 4 and 5, each point represents recordings from 3-5 preparations in drug-treated groups and 9-11 in the control group. Eight to 16 neurons were recorded from each preparation. the peak is advanced on day 2 to approximately CT 2 (Fig. 6 ). The mean phase advance induced by trifluoperazine treatment at CT 6-9 is 3.3 ± 0.4 hr. The changes produced by trifluoperazine at different times through the circadian cycle are summarized in Figure 7 . This shows that treatment during the subjective day produces phase advances in the range of 2-4 hr. There is a small delay at CT 21-0, which is significant (Fig. 8 ). With W-7, treatment at CT 3-4 and 6-9 produces phase advances; treatment at CT 0-2 and 13-16 has no effect; and treatment at CT 21-0 produces a small but not significant phase delay (Fig. 8) . In contrast, the inactive analogue of W-7, W-5, has no effect at any CT. Both trifluoperazine and W-7 produce phase changes at CT 7-8 in a dose-dependent manner (Fig. 9 ).
EXPERIMENT 3
The administration of trifluoperazine (0.5, 5, and 10 mg/kg) or calmidazolium (5 mg/kg) at CT 8 produces a phase advance in the free-running circadian locomotor rhythm (Fig. 10) . The magnitude and direction of phase shifts produced in vivo are dependent upon the time of administration. The PRC for trifluoperazine (10 mg/kg) is shown in Figure 11 . There are FIGURE 4. PRCs for treatment with calmodulin inhibitors: trifluoperazine (10 ~Lm), chlorpromazine (100 )JLM), and W-7 (50 Rm). All of the active calmodulin inhibitors show similar patterns, with large phase delays at CT 3 and large phase advances of CT 9. The inactive compound, W-5, has no significant effect. significant phase advances at CT 4 and 8. Treatments at CT 0, CT 12, and CT 16 all produce small but nonsignificant phase advances, and treatment at CT 20 produces a small but nonsignificant phase delay. Trifluoperazine produces phase changes at CT 8 in a dosedependent manner (Fig. 12 ). The maximum phase shift, at CT 8, is 0.78 ± 0.07 hr. Calmidazolium (5 mg/kg) at CT 8 produces a phase advance of 0.43 ± 0.8 hr (p < (0.05), whereas at CT 20 the change is not significant (delay of 0.14 ± 0.12 hr, p > (0.05).
DISCUSSION
The objective of this study was to investigate the effects of calmodulin inhibitors on circadian function in vivo and in vitro. The background for this is as follows. Calcium plays a major role in synaptic transmission and in circadian function (Shibata et al., 1984; Nakashima, 1986; McMahon and Block, 1987; Edmunds, 1988) . One major pathway by which calcium acts in neurons is through binding to calmodulin to activate a calmodulin kinase, and the initial intent of the study was to determine whether blocking this pathway would result in an alteration of circadian function expressed in vitro.
The in vivo component was then added to demonstrate that the in vitro effects could be interpreted to be lasting.
Administration of calmodulin inhibitors to intact animals produces small phase advances during the subjective day without phase changes at other CTs. As in other pharmacological studies (Zatz and Herkenham, 1981; Albers et al., 1984; Albers and Ferris, 1984; Earnest FIGURE 5 . Dose-response curves for effects of trifluoperazine and W-7 on the phase of firing rate at CT 9 and CT 3. The effects of both drugs are dose-dependent, with increasing phase advances occurring at CT 9 and increasing phase delays at CT 3 with increasing doses of each of the calmodulin inhibitors. and Turek, 1985; Johnson et al., 1989; Edgar et al., 1993) , the changes in phase occur in the cycle in which the treatment is administered, without evident transients. Thus, the effects must reflect changes in pacemaker function that are initiated within a fairly narrow time interval of susceptibility and expressed fully within a few hours. It is important to determine the nature of the drug effects, and this is more likely to be approachable by an in vitro analysis.
The effects of in vitro administration of calmodulin inhibitors differ from in vivo effects, depending upon the time after treatment at which they are assessed. In our studies, the early in vitro analysis was the first performed. In these experiments we used three treatments in addition to the calmodulin inhibitors that are known, or can be inferred, to affect circadian function in vivo as controls. Pentobarbital administration to the intact mouse (Ebihara et al., 1988 ) results in phase changes with a PRC similar to that for activity (Reebs and Mrosovsky, 1989; Van Reeth and Turek, 1989) . At the dose used in our study, pentobarbital produces electrical silence in the slice and does not produce acute alteration in the firing rate rhythm. Since the effect in vivo is likely to be atributable to the induction of locomotor activity, this lack of effect in vitro is not surprising. High potassium appears to us to be the equivalent of SCN stimulation in vivo (Rusak and Groos, 1982) , and it produces acute changes with a PRC that is generally similar. Optic chiasm stimulation also produces similar changes when studies in vitro in a paradigm of studying phase changes on the day after treatment (Shibata and Moore, 1993) . In both of these latter situations, then, the effects of in vitro treatments are quite similar to those obtained in vivo. Another example comes from use of protein synthesis inhibitors. In the hamster, both parenteral and intracerebral injection of anisomycin (Takahashi and Turek, 1987; Inouye et al., 1988) , or the parenteral administration of cycloheximide (Takahashi and Turek, 1987) , produces phase delays in th early subjective day FIGURE 6. Chronic effects of treatments on the circadian rhythm in SCN neuron firing rate in vitro. Firing rate is shown on the ordinate, and CT on the abscissa. Slices were prepared at CT 5. The control slices received vehicle into the medium for 1 hr at CT 7-8 (top panel) on the first day. On the second day, recordings were made throughout the subjective day. The plotted points are the 2-hr means ± SE of firing rates. Each point represents recordings from 8 to 12 units in one slice. The bottom panel shows the effect of trifluoperazine (TFP, 10 )JLM) at CT 7-8. and phase advances in the late subjective day. Cycloheximide in vitro produces phase changes similar in direction to those in vivo, but with a much greater magnitude. Thus, each of these treatments produces phase changes in vitro that are similar to those noted in vivo, and these data provide a foundation for the in vitro calmodulin inhibitor studies. With analysis of the firing rate rhythms performed 6 hr after calmodulin inhibitor administration, we observe apparent phase changes that are very similar among the various agents, and that are characterized by large phase delays during the early subjective day and phase advances during the late subjective day. With analysis performed in the cycle following the administration of the calmodulin inhibitors, there are apparent phase advances that are maximal with treatment during the CT 6-9 interval. The changes are specific to active compounds and are dosedependent. However, they are three to four times greater than those observed in vivo, and the phase advances recorded during the first cycle are approximately twice as great as those recorded during the second cycle.
How do we account for these differences in apparent phase changes induced by the same treatments acutely and after 1 day in vitro, and over many days in vivo? One explanation for the difference between the in vitro and in vivo data is that the in vitro data were obtained FIGURE 7. PRC for trifluoperazine administration compared to control. from rats and the in vivo data from hamsters. Another answer to this question is that the acute effects are atributable to a nonspecific action of the treatment affecting an output firing rate, without altering clock function. This explanation seems to us to have a potential problem. The times at which phase changes are induced, and their direction, are similar to the in vivo situation-with the possible exception of phase delays in the late subjective night-early subjective day, where changes are significant in vivo for only one compound. This suggests to us an alternative explanation that appears to us to have some attraction, and perhaps some validity. To discuss this, it is necessary to consider the organization of the SCN pacemaker.
In all likelihood, the SCN is comprised of a population of neurons that are individual circadian oscillators coupled into a network that functions as a pacemaker (Moore and Bernstein, 1989) . Whether all SCN neurons are oscillators, or only a subpopulation expressed circadian function, is unclear. Nevertheless, the neurons that are oscillators will be highly interconnected in the dense local circuitry of the SCN, and hence will be coupled into a network that functions as a circadian pacemaker. In the intact animal, this network is innervated by a series of afferent inputs-from the retina, the raphe serotonin neurons (Moore et al., 1978) , and from nearby hypothalamic areas (Pickard, 1982) . It also receives reciprocal input from areas that it innervates-the intergeniculate leaflet Moore, 1982, 1989) and the subparaventricular zone (Watts et al., 1987) . All of the sources of input are likely to have different patterns of activity and different responses to environmental and intrinsic stimuli. It would be our view that all of these may affect pacemaker phase and period, and that phase and period are maintained through a continuing dynamic integration of these influences. For lack of a better term, we would refer to this as &dquo;pacemaker homeostasis.&dquo; The significance of this concept is that it envisions entrainment not as an episodic resetting of the hands of a clock, but as a continuing process. It also implies that maintenance of phase and period requires an interaction of the pacemaker not only with environmental influences, but with intrinsic neural influences, and particularly those regions that receive direct input from the pacemaker.
If this construct is correct, it may imply that the SCN isolated in a slice lacks the input necessary for compensated response to a stimulus. Its response to a perturbing stimulus, as shown in this experiment, is large and uncompensated, but still constrained by the nature of the stimulus and the time of its administration. That is, calmodulin inhibitors produce apparent phase advances in the late subjective day. Over a longer interval after the stimulusone or two subsequent cycles, as shown here and in prior studies (Prosser and Gillette, 1991; Prosser et al., 1992; Shibata et al., 1992; Shibata and Moore, 1993 )-the response is reduced in amplitude, but still constrained with respect to the nature of the stimulus and time of administration. For example, the magnitude of the phase changes to calmodulin inhibitors remains dose-dependent, even though much reduced in amplitude. These responses are, however, still substantially larger (at least in the case of the calmodulin inhibitors) than the in vivo response. We would argue that one way to interpret this is to hypothesize that the initial response of the pacemaker in vitro is not compensated in a normal manner, because part of the circuitry involved in the compensated response is missing from the slice. If this is true, it indicates that slice data must be interpreted very carefully, and are most appropriately interpreted in the context of in vivo data.
What are the cellular mechanisms by which calmodulin inhibitors alter circadian function? The first possibility, as noted above, would be to prevent a calcium-calmodulin activation of a specific calmodulin kinase affecting cellular clock function. A second possibility would use the action of calmodulin inhibitors to increase cAMP levels (Berndt and Schwabe, 1973; Eliot et al., 1989) and to inhibit phosphodiesterase activity (Van Belle, 1984; Stoclet et al., 1987) . There is a rhythm in cAMP levels in the SCN (Murakami and Takahashi, 1983; Prosser and Gillette, 1991) , and cAMP administration to slices produces phase changes in the SCN firing rate rhythm very similar to those produced by calmodulin inhibitors (Prosser and Gillette, 1989) . Thus, the effect of calmodulin inhibi-FIGURE 11. PRC for the effects of trifluoperazine on the activity rhythm under constant conditions. CT is indicated on the abscissa, with CT 12 denoting the onset of activity. The open bars represent the saline control; the hatched bars represent trifluoperzine (10 mg/kg). Each point is the mean phase change ± SE. Numbers in brackets are the number of animals for each point. *p < 0.05, **p < 0.01 versus saline group (t test). tors on phase could reflect their action to increase cAMP levels. The determination of the exact mechanisms by which calmodulin inhibitors affect pacemaker function will clearly require further study.
There is one additional finding in our study that warrants discussion. The PRC obtained from administration of calmodulin inhibitors in vivo and in vitro is characterized particularly by phase advances during the subjective day. This is distinctly different from a light PRC in the intact animal or the PRC for direct SCN stimulation (Rusak and Groos, 1982) . This type of PRC has been noted increasingly often in recent years under a variety of circumstances. It is obtained with treatments that result in an acute induction of locomotor activity (see Reebs and Mrosovsky, 1989, and Van Reeth and Turek, 1989, for reviews). Similar changes are obtained by activation of the geniculohypothalamic tract (Johnson et al., 1989) or by infusion of neuropeptide Y into the SCN (Albers and Ferris, 1984) , a treatment that mimics geniculohypothalamic tract stimulation. Ablation of the intergeniculate leaflet, the source of the geniculohypothalamic tract, abolishes the phase-shifting effects of benzodiazepine-induced activity (Johnson et al., 1988; Biello et al., 1991) . Thus, we would conclude that calmodulin inhibitors act on the circadian clock through cellular mechanisms similar to those induced FIGURE 12. Dose-response effects for trifluoperazine-induced changes in the phase of the hamster activity rhythm. The vertical bars are means ± SE for the phase advances at CT 8. *p < 0.05, **p < 0.01 versus saline group (Duncan test). by geniculohypothalamic tract activation. We further conclude that this is a direct action on cellular clock mechanisms, both because the effects can be obtained in vivo and in vitro, and because they occur in vivo without producing locomotor activity.
